Star Metro - Zomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal Health

ANN ARBOR, MI / ACCESS Newswire / January 22, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, today announced that it has entered into a contract manufacturing and service agreement with Rahm Sensor Development, a technology company advancing contact-free, multi-sensor monitoring solutions for high-risk environments.

Under the agreement, Zomedica will manufacture Rahm's first commercial product, the Cell-Guardian^™, an advanced personnel monitoring device designed to improve safety and situational awareness in high-risk environments. Cell-Guardian™ is currently being deployed in correctional and institutional settings to enhance safety and situational awareness. Zomedica will also provide engineering services on an as-needed basis and Level One customer service, enabling Rahm to accelerate commercialization while leveraging Zomedica's established operational platform.

The agreement expands Zomedica's revenue model beyond the animal health channel by monetizing existing manufacturing and engineering capabilities. Management expects the partnership to generate incremental, contract-based revenue while improving utilization of existing assets and limiting incremental fixed costs.

"This agreement allows us to generate new revenue by leveraging assets we already own," said Larry Heaton, Chief Executive Officer of Zomedica. "It improves operating leverage, supports cash flow, and aligns with our disciplined approach to diversification without increasing fixed costs. We view this as a practical way to create shareholder value while maintaining focus on our core animal health business."

From an investor perspective, the opportunity is supported by the size and growth of adjacent monitoring and sensor markets. According to Grand View Research, the global wearable technology market was valued at approximately $84 billion in 2024 and is projected to reach $186 billion by 2030, reflecting a compound annual growth rate of 13.6%. Zomedica believes this market backdrop supports a measured expansion strategy focused on capital efficiency and execution discipline

"We chose Zomedica for their experienced team, established quality systems, and background operating in regulated medical device environments," said Vik Ramprakash, CEO of Rahm Sensor Development. "Cell-Guardian™ is our first commercial product, and this partnership allows us to accelerate market entry while building a strong manufacturing and support foundation for future growth."

As Rahm's product portfolio expands, the agreement provides a framework to evaluate Zomedica's participation in additional programs, creating the potential for recurring manufacturing and services revenue over time.

"This partnership is a clear example of disciplined diversification," said Greg Blair, Senior Vice President of Business Development and Strategic Planning at Zomedica. "By extending our existing capabilities into adjacent markets, we can unlock higher-margin revenue opportunities, improve asset efficiency, and build predictable, contract-based income streams."

Zomedica believes this partnership will contribute positively to revenue growth, margin expansion, and free cash flow over time, while strengthening the Company's strategic position as a diversified medical technology platform.

About Zomedica

Zomedica is a leading equine and companion animal health company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet^® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi^® line of therapeutic devices, the TRUFORMA^® diagnostic platform, the TRUVIEW^® digital cytology system, the VetGuardian^® Zero Touch™ monitoring system, and VETIGEL^® hemostatic gel, a revolutionary hemostatic agent that rapidly stops bleeding, all designed to empower veterinarians to deliver top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion annually. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $54.4 million in liquidity as of September 30, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as it works to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com

• LinkedIn: https://www.linkedin.com/company/zomedica

• Facebook: https://m.facebook.com/zomedica

• X (formerly Twitter): https://twitter.com/zomedica

• Instagram: https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the expected revenue may not materialize, the expenses may be greater than anticipated, Rahm Sensor Development may elect to purchase products from another vendor, the risks associated with the adoption of new products in the marketplace, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
[email protected]
1-734-369-2555

SOURCE: Zomedica Corp.

View the original press release on ACCESS Newswire

F.Leblanc--SMC